局部PDE4抑制剂通过抑制嗜碱性粒细胞IL-4改善特应性皮炎
本研究利用恶唑酮诱导的小鼠特应性皮炎模型,探究新型PDE4抑制剂地法米司特的作用机制。局部涂抹地法米司特可减轻皮肤炎症并降低IL-4表达,且在激发后第4天开始治疗仍有效。IL-4缺陷小鼠及嗜碱性粒细胞清除小鼠中地法米司特的治疗效应很小或没有,提示其可能通过抑制嗜碱性粒细胞产生IL-4来改善特应性皮炎炎症。
要点
- 局部地法米司特可减轻恶唑酮诱导的小鼠皮肤炎症并降低IL-4表达。
- 在IL-4缺陷或嗜碱性粒细胞清除小鼠中,地法米司特的治疗效应很小或没有。
- 地法米司特部分通过抑制ERK磷酸化来抑制嗜碱性粒细胞IL-4产生。
核心结论
- 地法米司特似乎通过抑制皮肤病灶中嗜碱性粒细胞的IL-4产生来改善特应性皮炎炎症。
研究设计与样本
- 本研究采用恶唑酮诱导的小鼠过敏性皮肤炎症模型(常用作特应性皮炎模型),分析新型PDE4抑制剂地法米司特的作用。
主要发现
- 局部涂抹地法米司特可改善皮肤炎症并降低IL-4表达,即使在恶唑酮激发后第4天开始治疗仍显示治疗效应。
- IL-4缺陷小鼠的皮肤炎症较野生型小鼠轻,且地法米司特治疗几乎没有进一步治疗效应。
- 清除嗜碱性粒细胞的小鼠中地法米司特的治疗效应也很小或没有,嗜碱性粒细胞是皮肤病灶中IL-4的主要产生者。
- 皮肤病灶中聚集的嗜碱性粒细胞显示编码PDE4家族B亚型的Pde4b表达高度上调。
- 地法米司特至少部分通过抑制ERK磷酸化来抑制体外激活的嗜碱性粒细胞产生IL-4。
临床怎么用
- 原文未提供临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phosphodiesterase 4 inhibitors have been approved for the treatment of atopic dermatitis. However, the cellular and molecular mechanisms underlying their therapeutic effect remain to be fully elucidated. In this study, we addressed this unsolved issue by analyzing the action of difamilast, a novel phosphodiesterase 4 inhibitor, on an oxazolone-induced skin allergic inflammation commonly used as a mouse model of atopic dermatitis. Topical application of difamilast ameliorated skin inflammation in association with reduced IL-4 expression even when the treatment commenced 4 days after the initiation of oxazolone challenge, showing its therapeutic effect on atopic dermatitis. IL-4-deficient mice displayed milder skin inflammation than did wild-type mice, and the difamilast treatment had little or no further therapeutic effect. This was also the case in mice depleted of basophils, predominant producers of IL-4 in the skin lesion, suggesting that difamilast may act on basophils. Notably, basophils accumulating in the skin lesion showed highly upregulated expression of Pde4b encoding the B subtype of the phosphodiesterase 4 family. Difamilast suppressed IL-4 production from basophils activated in vitro, at least in part, through inhibition of ERK phosphorylation. Taken together, difamilast appeared to ameliorate atopic dermatitis inflammation through the suppression of basophil IL-4 production in the skin lesion.
引用
- Takahashi K, Miyake K, Ito J, et al. Topical Application of a PDE4 Inhibitor Ameliorates Atopic Dermatitis through Inhibition of Basophil IL-4 Production. J Invest Dermatol. 2023. PMID: 37827277. doi:10.1016/j.jid.2023.09.272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。